C H J Lamers

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. ncbi Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer
    Cor H J Lamers
    Department of Medical Oncology, Subdivision of Clinical and Tumor Immunology, Erasmus Medical Center Daniel, Rotterdam, The Netherlands
    Cancer Gene Ther 9:613-23. 2002
  2. ncbi Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity
    Cor Hj Lamers
    Department of Medical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Mol Ther 21:904-12. 2013
  3. ncbi Long-term stability of T-cell activation and transduction components critical to the processing of clinical batches of gene-engineered T cells
    Cor H J Lamers
    Department of Medical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cytotherapy 15:620-6. 2013
  4. ncbi Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells
    Cor H J Lamers
    Department of Medical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Blood 117:72-82. 2011
  5. ncbi Gibbon ape leukemia virus poorly replicates in primary human T lymphocytes: implications for safety testing of primary human T lymphocytes transduced with GALV-pseudotyped vectors
    Cor H J Lamers
    Unit of Clinical and Tumor Immunology, Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, AE Rotterdam, The Netherlands
    J Immunother 32:272-9. 2009
  6. ncbi Retronectin-assisted retroviral transduction of primary human T lymphocytes under good manufacturing practice conditions: tissue culture bag critically determines cell yield
    C H J Lamers
    Laboratory of Clinical and Tumor Immunology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cytotherapy 10:406-16. 2008
  7. ncbi Retroviral vectors for clinical immunogene therapy are stable for up to 9 years
    C H J Lamers
    Department of Medical Oncology, Laboratory of Clinical and Tumor Immunology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer Gene Ther 15:268-74. 2008
  8. ncbi Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo
    Cor H J Lamers
    Laboratory for Clinical and Tumor Immunology, Department of Medical Oncology, Erasmus MC, Daniel den Hoed Cancer Center, PO Box 5201, 3008 AE, Rotterdam, The Netherlands
    Cancer Immunol Immunother 56:1875-83. 2007
  9. ncbi Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-s
    C H J Lamers
    Unit Clinical and Tumor Immunology, Department of Medical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cytotherapy 8:542-53. 2006
  10. ncbi Adoptive immuno-gene therapy of cancer with single chain antibody [scFv(Ig)] gene modified T lymphocytes
    C H J Lamers
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Biol Regul Homeost Agents 18:134-40. 2004

Collaborators

Detail Information

Publications18

  1. ncbi Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer
    Cor H J Lamers
    Department of Medical Oncology, Subdivision of Clinical and Tumor Immunology, Erasmus Medical Center Daniel, Rotterdam, The Netherlands
    Cancer Gene Ther 9:613-23. 2002
    ..This clinical protocol routinely yields 30-65% scFvG250 ch-Rec(POS) T lymphocytes in both healthy donors and RCC patients...
  2. ncbi Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity
    Cor Hj Lamers
    Department of Medical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Mol Ther 21:904-12. 2013
    ..We provide in-patient proof that the observed "on-target" toxicity is antigen-directed and can be prevented by blocking antigenic sites in off-tumor organs and allowing higher T cell doses...
  3. ncbi Long-term stability of T-cell activation and transduction components critical to the processing of clinical batches of gene-engineered T cells
    Cor H J Lamers
    Department of Medical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cytotherapy 15:620-6. 2013
    ....
  4. ncbi Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells
    Cor H J Lamers
    Department of Medical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Blood 117:72-82. 2011
    ....
  5. ncbi Gibbon ape leukemia virus poorly replicates in primary human T lymphocytes: implications for safety testing of primary human T lymphocytes transduced with GALV-pseudotyped vectors
    Cor H J Lamers
    Unit of Clinical and Tumor Immunology, Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, AE Rotterdam, The Netherlands
    J Immunother 32:272-9. 2009
    ....
  6. ncbi Retronectin-assisted retroviral transduction of primary human T lymphocytes under good manufacturing practice conditions: tissue culture bag critically determines cell yield
    C H J Lamers
    Laboratory of Clinical and Tumor Immunology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cytotherapy 10:406-16. 2008
    ..Critical to our successful clinical-scale transductions of patient T cells was the use of Retronectin in combination with Lifecell X-foldtrade mark cell culture bags...
  7. ncbi Retroviral vectors for clinical immunogene therapy are stable for up to 9 years
    C H J Lamers
    Department of Medical Oncology, Laboratory of Clinical and Tumor Immunology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer Gene Ther 15:268-74. 2008
    ..These data provide evidence that in terms of 'life expectancy' the production and storage of clinical batches of RTVsup for gene therapy warrants the corresponding professional and financial risks...
  8. ncbi Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo
    Cor H J Lamers
    Laboratory for Clinical and Tumor Immunology, Department of Medical Oncology, Erasmus MC, Daniel den Hoed Cancer Center, PO Box 5201, 3008 AE, Rotterdam, The Netherlands
    Cancer Immunol Immunother 56:1875-83. 2007
    ..Here, we investigate whether or not the in vivo activity of the infused scFv(G250)(+) T cells is reflected by changes of selected immune parameters measured in peripheral blood...
  9. ncbi Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-s
    C H J Lamers
    Unit Clinical and Tumor Immunology, Department of Medical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cytotherapy 8:542-53. 2006
    ..We describe the validation of our clinical protocol for gene transduction and expansion of human T lymphocytes...
  10. ncbi Adoptive immuno-gene therapy of cancer with single chain antibody [scFv(Ig)] gene modified T lymphocytes
    C H J Lamers
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Biol Regul Homeost Agents 18:134-40. 2004
    ..Currently, we evaluate this concept in a clinical protocol to treat patients with metastatic renal cell cancer (RCC) using autologous RCC-specific gene-modified T lymphocytes...
  11. ncbi Parallel detection of transduced T lymphocytes after immunogene therapy of renal cell cancer by flow cytometry and real-time polymerase chain reaction: implications for loss of transgene expression
    C H J Lamers
    Laboratory of Clinical and Tumor Immunology, Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, 3008 AE Rotterdam, The Netherlands
    Hum Gene Ther 16:1452-62. 2005
    ..These results suggest loss of scFv(G250) membrane expression on adoptive transfer, which would have important implications for the antitumor efficacy of this form of immunogene therapy...
  12. ncbi Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: implications for clinical immunogene therapy of cancer
    C H J Lamers
    Unit of Clinical and Tumor Immunology, Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer Gene Ther 13:503-9. 2006
    ..The improved functional transduction efficiency together with a limited increase in the number of integrations per recipient cell, made us select Phoenix clone 58 for our clinical immunogene therapy study...
  13. ncbi T-lymphocyte reconstitution following rigorously T-cell-depleted versus unmodified autologous stem cell transplants
    P A W te Boekhorst
    Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands
    Bone Marrow Transplant 37:763-72. 2006
    ..This susceptibility to apoptosis would interfere with a swift and sustained CD4(+) T-cell regeneration post SCT...
  14. ncbi Bone-marrow transplantation fails to halt intrathecal lymphocyte activation in multiple sclerosis
    T Mondria
    Department of Neurology, Erasmus University Medical School, Erasmus MC, 3000 CA Rotterdam, The Netherlands
    J Neurol Neurosurg Psychiatry 79:1013-5. 2008
    ..Given the presumed key role for autoreactive lymphocytes in multiple sclerosis (MS), treatment strategies have been developed to ablate lymphocyte activity. Intrathecal lymphocyte activation can be measured by CSF-soluble(s)CD27...
  15. ncbi Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses
    Johanna E A Portielje
    Department of Medical Oncology, Erasmus MC - Daniel den Hoed, 3075 EA Rotterdam, The Netherlands
    Clin Cancer Res 9:76-83. 2003
    ..The steady increment of IL-10 plasma levels may mediate the observed down-regulation of clinical and immunological effects...
  16. ncbi mRNA levels of CD31, CD144, CD146 and von Willebrand factor do not serve as surrogate markers for circulating endothelial cells
    Michiel H Strijbos
    Laboratory of Translational Tumorimmunolgy, Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Thromb Haemost 104:318-26. 2010
    ..We conclude that mRNA levels of CD31, CD144, CD146 and vWf in whole blood as detected by real time RT-PCR cannot be used as biomarkers for end-stage endothelial cells such as CEC...
  17. ncbi Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors
    Valérie Vantomme
    GlaxoSmithKline Biologicals, Rixensart, Belgium
    J Immunother 27:124-35. 2004
    ..It is concluded that vaccination of advanced cancer patients with MAGE-3 self-antigen in AS02B adjuvant is able to elicit MAGE-3-specific antibody and a T-cell response...
  18. ncbi Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience
    Cor H J Lamers
    J Clin Oncol 24:e20-2. 2006